The FDA options are vast.
They can approve.
Thdy can reject the drug and remove it from sale.
They can require more data, change trial endpoints etc.
Because the the safety issues have been addressed, i would guess on redefining endpoints and trial with mire data required. But that is an unqualified guess.
We find out soon.
- Forums
- ASX - By Stock
- PER
- Sarepta FDA Hearing
PER
percheron therapeutics limited
Add to My Watchlist
5.88%
!
0.8¢

Sarepta FDA Hearing, page-9
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
0.8¢ |
Change
-0.001(5.88%) |
Mkt cap ! $8.699M |
Open | High | Low | Value | Volume |
0.9¢ | 0.9¢ | 0.8¢ | $16.64K | 2.010M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
24 | 6525662 | 0.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.9¢ | 1987416 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
24 | 6525662 | 0.008 |
5 | 2239427 | 0.007 |
3 | 2016833 | 0.006 |
3 | 1699997 | 0.005 |
1 | 1475000 | 0.004 |
Price($) | Vol. | No. |
---|---|---|
0.009 | 1987416 | 4 |
0.010 | 2301175 | 7 |
0.011 | 2440000 | 5 |
0.012 | 2658324 | 5 |
0.013 | 1500000 | 3 |
Last trade - 15.25pm 18/07/2025 (20 minute delay) ? |
Featured News
PER (ASX) Chart |